Key result
Captopril controls blood pressure in scleroderma hypertension, lowering mean pressure by ~21 mmHg despite persistent renal risk.
Observational (n=12)
Answers are grounded in this paper and cite their sources.
Twelve scleroderma patients with hypertension, seven of whom had malignant hypertension and renal failure of scleroderma renal crisis, were treated with captopril. The first dose lowered mean pressure in all patients by 21.3 mmHg; in 6 patients it relieved encephalopathy. Blood pressure was controlled in all patients. Two of 7 patients with scleroderma renal crisis had improvement in renal function; the 5 patients who did not have malignant hypertension improved or stabilized. Despite good pressure control, however, renal failure developed in 5 patients with scleroderma renal crisis. The data indicated that captopril is effective antihypertensive therapy in scleroderma and, when given early, may prevent renal failure and death.
No takes yet. Share an insight, caveat, or question.
Whitman et al. (1982) conducted an observational in Hypertensive scleroderma (including scleroderma renal crisis) (n=12). Captopril was evaluated on Blood pressure control and renal function improvement/stabilization (MD -21.3 mmHg (first-dose mean pressure reduction)). Captopril controlled blood pressure in 100% of hypertensive scleroderma patients, though 5 of 7 with renal crisis still developed renal failure.
Synapse has enriched 10 related papers. Consider them for comparative context: